Ocugen Stock News

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the pricing of its underwritten public offering of approximately 15,973,420 million shares of its common stock for gross proceeds of approximately $53.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen. The offering is expected to close on or about February 25, 2022, subject to customary closing conditions. In addition, Ocugen has granted to the underwriter a 30-day option to purchase up to approximately 2,396,013 million additional shares of its common stock.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen''s path to entry in the North American market is highly uncertain, making OCGN stock a remarkably risky bet at this point. The post Ocugen Is Too Uncertain as Time Runs Out for Covaxins Approval appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

COVID-19 vaccine developer, Ocugen (OCGN) has lost ~12% in the post-market on Tuesday after the company announced an underwritten public offering of of its common stock.A 30-day

MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure

Tuesday turned out to be a good day for Ocugen (OCGN) investors. Shares took off after the company disclosed that the FDA had removed the clinical hold placed on th

A host of worries pulled the broader market lower after the long holiday weekend.

DWAC stock rallied on news that Donald Trump''s TRUTH Social app got strong initial downloads. DNUT rose on earnings. FDA decisions sent OCGN and FIXX in opposite directions.

Gainers: Indonesia INDO +79%.Meritor MTOR +45%.Ocugen OCGN +22%.Datasea (DTSS) +20%.IronNet (IRNT) +20%.Riley Exploration Permian REPX +19%.Arteris (AIP) +17%.Houghton Mifflin

The FDA lifted a clinical hold that had been preventing Ocugen from starting a U.S.-based phase 3 clinical study of its COVID-19 vaccine.

The FDA lifted a clinical hold that had been preventing Ocugen from starting a U.S.-based phase 3 clinical study of its COVID-19 vaccine.

Ocugen Inc (NASDAQ: OCGN ) shares are trading higher by 23.8% at $4.28 Tuesday morning after the company announced the FDA lifted its clinical hold on the company''s COVID-19 vaccine study in the US. "We are pleased to be able to move our clinical program for Covaxin forward, which we hope will Full story available on Benzinga.com

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of OCGN stock are flying higher after the FDA lifted its clinical hold on Covaxin, the company''s coronavirus drug candidate. The post OCGN Stock Alert: Why Is Ocugen Heating Up Today? appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

Investors are grappling with some troublesome headlines from Russia-Ukraine. JPMorgan says this is what you worry about.

What you need to know about trading penny stocks on February 22nd The post Trading Penny Stocks? Top Stock Market News for February 22nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and I